Carna Biosciences Inc
TSE:4572
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
202
497
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
Carna Biosciences Inc
TSE:4572
|
8.3B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
236.4B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
166B USD |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.6B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.1B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
279.2B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.7B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20.3B EUR |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
Carna Biosciences Inc
Glance View
Carna Biosciences, Inc. engages in the drug discovery business. The company is headquartered in Kobe, Hyogo-Ken and currently employs 64 full-time employees. The company went IPO on 2008-03-25. The firm operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Carna Biosciences Inc is -376.5%, which is below its 3-year median of -196.4%.
Over the last 3 years, Carna Biosciences Inc’s Operating Margin has decreased from -4.7% to -376.5%. During this period, it reached a low of -376.5% on Oct 30, 2025 and a high of -4.7% on Aug 30, 2022.